Publications
Links to our latest financial and sustainability reports and other recent publications.
Grifols’ fourth quarter and year-end 2024 results.
Showing 222 search results
Grifols Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients
Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029
Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow
Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner
Grifols completes enrollment of second cohort in first-in-human Alpha-1 15% subcutaneous option for treating alpha1-antitrypsin deficiency
Grifols collaborates with startup FcR Therapeutics to develop recombinant therapies for autoimmune diseases
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
If you're a journalist or media professional with a question, contact our media relations team.